Cytokine Based Therapies and Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Cytokine Based Therapies and Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Healthcare IT

Report Description


Cytokines are produced by broad range of cells including cells of immune system of human body with respect to complex immune responses. Cytokines aid in intercellular communication in immune response because they are cell signaling molecules and trigger the movement of cells toward sites of inflammation, infection and trauma. Cytokines can be categorized as peptides, proteins, and glycoproteins. Cytokines and their receptors are used in various treatment therapies for inflammatory and immune disorders, infectious diseases (such as HIV and HCV), and oncology; due to their ability to boost immune responses.

The market for cytokine based therapies and inhibitors has impressive growth prospects, majorly due to multi-faceted use of cytokines in diagnostic, therapeutic, and prophylactic applications and increased feasibility of chemical synthesis of cytokines. On the contrary, factors such as short half-lives of drug, lack of target-specific treatment and technical expertise, high cost involved in new product development, and high therapy cost may restrain the market for cytokines in the next few years. Cytokines have inherently short half-life, which necessitates prolonged administration of cytokine therapies. This is a major problem in maintaining an effective dose over a long period. This becomes even greater issue when cytokine is administered systematically. In the meantime, cancer immunotherapy has progressed in the area of specificity, where the cytokine therapy cannot possibly improve. This is perhaps the biggest drawback of the cytokine therapy. Development of cytokine-based therapies offers lucrative growth opportunities to market players, as it is one of the prominent areas of immunotherapies. Roche Diagnostics, Immunochemistry Technologies LLC, and Merck/Schering Plough are some of the companies operating in the immunotherapies market.

The global cytokine based therapies and inhibitors market has been segmented in terms of cytokine type, therapeutic application, and geography. In terms of cytokine type, the market has been segmented into tumor necrosis factor (anti-TNF drugs), interleukins (IL), interferon (IFN), epidermal growth factor (EGF), and chemokine. Based on therapeutic application, the market has been categorized into cancer & malignancies, inflammatory & immune disorders (asthma/airway inflammation, arthritis), infectious diseases (such as HIV and HCV), and others. In terms of geography, the global cytokines market has been segmented into North America, Europe, Asia Pacific, and Rest of World.

Interferons are induced in response to viral infections. INTRON A (Merck Sharp & Dohme Corp.) and Pegasys (Genentech, Inc.) are some of the approved brands of cytokine interferon. Tumor necrosis factors are basically involved in the regulation of cell proliferation and apoptosis and is instrumental in genesis of liver, cachexia, and anemia by activating platelets. Anti-TNF drugs treat inflammatory conditions such as rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and psoriasis. These drugs block tumor necrosis factor (TNF), an inflammation-causing substance, and thereby, reduce inflammation and stop disease progression.

Major players are developing and adding cytokine drugs to their portfolios. In July 2017, Merck launched a biosimilar anti TNF drug RENFLEXIS. This drug is the second FDA approval for a biosimilar of its original biologic medicine Remicade (infliximab) developed by Johnson & Johnson. The first biosimilar was Pfizer and Celltrion’s Inflectra, which was approved in July 2016.

Key players operating in the global cytokine based therapies and inhibitors market are AbbVie Inc., GlaxoSmithKline LLC, Eli Lilly and Company, Genentech, Inc., Roche Diagnostics, Immunochemistry Technologies LLC, Merck Sharp & Dohme Corp., Amgen Inc., Novartis, Pfizer, Johnson & Johnson, Sanofi, Teva, and Genentech, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market 

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients